MLXIPL and hypertriglyceridemia: While knockdown of hepatic ChREBP attenuates fructose-induced hypertriglyceridemia and insulin resistance, this occurs without reductions in steatosis potentially due to its countervailing effects to reduce export of liver triglyceride in the form of VLDL [13,15].